Kevin O'Leary, a big-name investor known for his no-nonsense approach to business, has a unique strategy for dealing with ...

Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...

Investors with a lot of money to spend have taken a bullish stance on Norwegian Cruise Line NCLH. And retail traders should ...

DirecTV and Dish Network are in advanced talks to merge, potentially creating the largest U.S. pay-TV provider with 20 ...

Nvidia Inc. (NASDAQ: NVDA) shares are trading lower Friday, along with the broader semiconductor sector, pulling back after a ...

Just look at Andrew “Boz” Bosworth, Meta's CTO, the guy who invented Facebook's News Feed. Now, he's leading Meta's charge ...

BlackBerry stock plunges on upbeat Q2 report, beats revenue and EPS estimates with strength in IoT and cybersecurity. RBC ...

In 2016, Warren Buffett, the legendary investor and CEO of Berkshire Hathaway, openly criticized Donald Trump during his ...

Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other ...

Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations.

Analysts' ratings for Graco GGG over the last quarter vary from bullish to bearish, as provided by 4 analysts. The following ...

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...